SuperworthAlkermes plc. EPS ALKS
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- $0.38
- Latest quarter, Q2 FY26
- $0.00
- −100% on a year earlier
- Fiscal year 2025
- $1.43
- −34% on the year before
Alkermes plc.'s earnings per share was $0.38 over the twelve months to Jun 30, 2026, down 82% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.00, down 100% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.43 | −34% |
| FY2024 | $2.17 | +4% |
| FY2023 | $2.09 | n/a |
| FY2022 | −$0.96 | n/a |
| FY2021 | −$0.30 | n/a |
| FY2020 | −$0.70 | n/a |
| FY2019 | −$1.26 | n/a |
| FY2018 | −$0.89 | n/a |
| FY2017 | −$1.03 | n/a |
| FY2016 | −$1.37 | n/a |
| FY2015 | −$1.52 | n/a |
| FY2014 | −$0.21 | −217% |
| FY2013 | $0.18 | +38% |
| FY2013 | $0.13 | n/a |
| FY2012 | −$0.96 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.00 | −100% | $0.38 | |
| Q1 FY26 | −$0.40 | −408% | $0.90 | |
| Q4 FY25 | $0.29 | −67% | $1.43 | |
| Q3 FY25 | $0.49 | −11% | $2.02 | |
| Q2 FY25 | $0.52 | −2% | $2.08 | |
| Q1 FY25 | $0.13 | −38% | $2.09 | |
| Q4 FY24 | $0.88 | +29% | $2.17 | |
| Q3 FY24 | $0.55 | +96% | $1.97 | |
| Q2 FY24 | $0.53 | −62% | $1.70 | |
| Q1 FY24 | $0.21 | n/a | $2.55 | |
| Q4 FY23 | $0.68 | n/a | $2.09 | |
| Q3 FY23 | $0.28 | n/a | $1.24 |
Against its peers
Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| JAZZJazz Pharmaceuticals | $14.62 | |
| Peer median | $1.00 |
Where Alkermes plc. ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Alkermes plc.
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.